GlassScriptPhysician profile
Michael W Moats
NPI 1750360889
$2,274.14
in general payments reported to CMS, 2019-2025
20 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $267 · 2021: $228 · 2022: $145 · 2023: $320 · 2024: $356 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.25 | 2019-2025 | |
| Pfizer INC. | $243.63 | 2021-2025 | |
| Lilly USA, LLC | $184.99 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $150.18 | 2019-2025 | |
| Genzyme Corporation | $142.77 | 2019-2022 | |
| Ucb, INC. | $141.37 | 2019-2023 | Bimzelx |
| Janssen Scientific Affairs, LLC | $124.88 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.44 | 2019-2023 | Targretin |
| Janssen Biotech, INC. | $84.84 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $70.87 | 2019 | |
| Galderma Laboratories, L.P. | $52.95 | 2021 | |
| Celgene Corporation | $34.61 | 2019 | |
| Strata Skin Sciences, INC. | $33.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Vyne Pharmaceuticals INC. | $29.36 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.56 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.32 | 2019 | |
| Leo Pharma INC. | $16.44 | 2022 | |
| Allergan, INC. | $14.07 | 2020 | |
| Prugen, INC. Pharmaceuticals | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.